Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HHSN268200425210C |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Purpose of this study is to:
This first phase will be a prospective cohort study. We will validate the bedside tool in at least 4 adult and at least 4 pediatric ICUs and if necessary we will modify the bedside tool. The computerized bedside tool will be considered refined if >90% of the generated instructions are accepted and if the percent of glucose values in the 70-110 mg/dl range are equivalent to our pilot experience rate of 55%, and if the rate of glucose values less than or equal to 40 mg/dl is less than 0.5% of glucose measurements.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| eProtocol | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| glucose control with computer generated recommendations | Procedure | Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose. |
| Measure | Description | Time Frame |
|---|---|---|
| The primary outcome variable during Phase I will be the acceptability of the eProtocol-insulin instructions (compliance of bedside clinicians with instructions: more than 90 % of all instructions accepted by the bedside clinician). | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of glucose determinations within the range of 70-110 mg/dl (3.9-6.1 mMol/l) | 3 years | |
| Nursing perception of workload in comparison to ordinary care | 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alan H Morris, MD | Contact | 801-408-1610 | Alan.Morris@intermountainmail.org |
| Name | Affiliation | Role |
|---|---|---|
| Alan H Morris, MD | Intermountain Medical Center, Murray, Utah | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale University | Completed | New Haven | Connecticut | 05520 | United States | |
| Johns Hopkins University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Recruiting |
| Baltimore |
| Maryland |
| 21205 |
| United States |
|
| Massachusetts General Hospital | Withdrawn | Boston | Massachusetts | 02114 | United States |
| Baystate Medical Center | Active, not recruiting | Springfield | Massachusetts | 01199 | United States |
| Wake Forest Medical Center | Recruiting | Winston-Salem | North Carolina | 27157 | United States |
|
| Pennsylvania State Children's Hospital | Completed | Hersey | Pennsylvania | 17033 | United States |
| Children's Hospital of Philadelphia | Completed | Philadelphia | Pennsylvania | 19104 | United States |
| Vanderbilt University | Completed | Nashville | Tennessee | 37232 | United States |
| LDS Hospital | Recruiting | Salt Lake City | Utah | 84143 | United States |
|
| Primary Children's Hospital | Completed | Salt Lake City | Utah | 84143 | United States |
| University of Virginia | Active, not recruiting | Charlottesville | Virginia | 22908 | United States |
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D006943 | Hyperglycemia |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006946 | Hyperinsulinism |
Not provided
Not provided